Loay Kamel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Loay Kamel has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Hussain
School of Medicine, Royal College of Surgeons in Ireland, Medical University of Bahrain (RCSI-Bahrain), Busaiteen P.O. Box 15503, Bahrain
2 shared publications - Ahmed Elmewafy
The University of Sheffield, Western Bank Sheffield UK
2 shared publications Aliya A. Khan
Division of Endocrinology and Metabolism, McMaster University, Hamilton, Ontario, Canada
1 shared publication- Dalal S. Ali
Division of Endocrinology and Metabolism, McMaster University, Hamilton, Ontario, Canada
1 shared publication - Eyad Jamileh
School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK
1 shared publication Hany Gamal
School of Medicine St. George′s University St. George′s Grenada
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2026 (1)
Prognostic Value of Heart‐Type Fatty Acid‐Binding Protein in Patients With Acute Coronary Syndrome: A Systematic Review and Meta‐Analysis
Introduction: Heart‐type fatty acid‐binding protein (H‐FABP) is rapidly released following myocardial injury, but its prognostic significance in acute coronary syndrome (ACS) remains uncertain. We evaluated the association between elevated H‐FABP and adverse clinical outcomes in confirmed or suspected ACS. Methods: PubMed, Embase, CENTRAL, Web of Science and Scopus were searched from inception to 30 August 2026 without date restriction. Studies assessing diagnostic and/or prognostic relevance of circulating H‐FABP in adults with confirmed or suspected ACS were eligible. Prognostic outcomes included all‐cause mortality, major adverse cardiovascular events (MACE), heart failure (HF)–related hospitalisation and recurrent myocardial infarction (MI). Risk of bias was assessed using QUIPS. Crude odds ratios (ORs) from extractable 2 × 2 event data were pooled using inverse‐variance random‐effects models with restricted maximum‐likelihood estimation. Results: Twelve studies were included, with five contributing to meta‐analysis. Elevated H‐FABP was associated with higher odds of all‐cause mortality (OR 5.68; 95% CI 3.98–8.09; I 2 = 30 % ), MACE (OR 4.56; 95% CI 1.97–10.55; I 2 = 47 % ), HF‐related hospitalisation (OR 4.29; 95% CI 2.94–6.26; I 2 = 0 % ) and recurrent MI (OR 1.65; 95% CI 1.15–2.37; I 2 = 0 % ). Pooled estimates were unadjusted; seven studies were synthesised narratively. Conclusion: Elevated H‐FABP is associated with adverse outcomes in ACS, but current evidence does not establish independent prognostic value. Further prospective studies should determine whether H‐FABP adds predictive value beyond established clinical and biochemical risk markers.
- 1 January 2026
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2026 (1)
Open AccessPrognostic Value of Heart‐Type Fatty Acid‐Binding Protein in Patients With Acute Coronary Syndrome: A Systematic Review and Meta‐Analysis
Introduction: Heart‐type fatty acid‐binding protein (H‐FABP) is rapidly released following myocardial injury, but its prognostic significance in acute coronary syndrome (ACS) remains uncertain. We evaluated the association between elevated H‐FABP and adverse clinical outcomes in confirmed or suspected ACS. Methods: PubMed, Embase, CENTRAL, Web of Science and Scopus were searched from inception to 30 August 2026 without date restriction. Studies assessing diagnostic and/or prognostic relevance of circulating H‐FABP in adults with confirmed or suspected ACS were eligible. Prognostic outcomes included all‐cause mortality, major adverse cardiovascular events (MACE), heart failure (HF)–related hospitalisation and recurrent myocardial infarction (MI). Risk of bias was assessed using QUIPS. Crude odds ratios (ORs) from extractable 2 × 2 event data were pooled using inverse‐variance random‐effects models with restricted maximum‐likelihood estimation. Results: Twelve studies were included, with five contributing to meta‐analysis. Elevated H‐FABP was associated with higher odds of all‐cause mortality (OR 5.68; 95% CI 3.98–8.09; I 2 = 30 % ), MACE (OR 4.56; 95% CI 1.97–10.55; I 2 = 47 % ), HF‐related hospitalisation (OR 4.29; 95% CI 2.94–6.26; I 2 = 0 % ) and recurrent MI (OR 1.65; 95% CI 1.15–2.37; I 2 = 0 % ). Pooled estimates were unadjusted; seven studies were synthesised narratively. Conclusion: Elevated H‐FABP is associated with adverse outcomes in ACS, but current evidence does not establish independent prognostic value. Further prospective studies should determine whether H‐FABP adds predictive value beyond established clinical and biochemical risk markers.
- Open Access
- 11 September 2025
- Published by Elsevier in AACE Endocrinology and Diabetes
- Vol. 12 (4) , 304-307
Reclassification of Hypophosphatemic Bone Disease as X-Linked Hypophosphatemia Following Genetic Testing in Adulthood
- 11 September 2025
- Published by Elsevier in AACE Endocrinology and Diabetes
- Vol. 12 (4) , 304-307
Open AccessReclassification of Hypophosphatemic Bone Disease as X-Linked Hypophosphatemia Following Genetic Testing in Adulthood